和誉(02256.HK)附属与艾力斯就肺癌联合治疗达合作协议

阿斯达克财经
24 Mar

和誉-B(02256.HK) 公布,旗下附属公司和誉医药与艾力斯(688578.SH) 达成合作协议,探索将和誉医药在研的口服PD-L1抑制剂“ABSK043”,与艾力斯的“KRAS-G12C”抑制剂枸橼酸戈来雷塞片,联合用于治疗KRAS-G12C突变的非小细胞肺癌患者。(js/w)

(港股报价延迟最少十五分钟。) (A股报价延迟最少十五分钟。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10